Atherosclerosis最新文献_第2页

Nucleic acid liquid biopsies in cardiovascular disease: Cell-free RNA liquid biopsies in cardiovascular disease 心血管疾病中的核酸液体活检：心血管疾病中的无细胞 RNA 液体活检。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118584

Smriti Sharma , Tyler Artner , Klaus T. Preissner , Irene M. Lang

{"title":"Nucleic acid liquid biopsies in cardiovascular disease: Cell-free RNA liquid biopsies in cardiovascular disease","authors":"Smriti Sharma , Tyler Artner , Klaus T. Preissner , Irene M. Lang","doi":"10.1016/j.atherosclerosis.2024.118584","DOIUrl":"10.1016/j.atherosclerosis.2024.118584","url":null,"abstract":"<div><div>Cardiovascular diseases (CVD) and their complications continue to be the leading cause of mortality globally. With recent advancements in molecular analytics, individualized treatments are gradually applied to the diagnosis and treatment of CVD. In the field of diagnostics, liquid biopsy combined with modern analytical technologies is the most popular natural source to identify disease biomarkers, as has been successfully demonstrated in the cancer field. While it is not easy to obtain any diseased tissue for different types of CVD such as atherosclerosis, deep vein thrombosis or stroke, liquid biopsies provide a simple and non-invasive alternative to surgical tissue specimens to obtain dynamic molecular information reflecting disease states. The release of cell-free ribonucleic acids (cfRNA) from stressed/damaged/dying and/or necrotic cells is a common physiological phenomenon. CfRNAs are a heterogeneous population of various types of extracellular RNA found in body fluids (blood, urine, saliva, cerebrospinal fluid) or in association with vascular/atherosclerotic tissue, offering insights into disease pathology on a diagnostic front. In particular, cf-ribosomal RNA has been shown to act as a damaging molecule in several cardio-vascular disease conditions. Moreover, such pathophysiological functions of cfRNA in CVD have been successfully antagonized by the administration of RNases. In this review, we discuss the origin, structure, types, and potential utilization of cfRNA in the diagnosis of CVD. Together with the analysis of established CVD biomarkers, the profiling of cfRNA in body fluids may thereby provide a promising approach for early disease detection and monitoring.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118584"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142279900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Coronary artery calcium density progression: Should we measure it? 冠状动脉钙密度进展：我们应该测量它吗？

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118618

Alexander C. Razavi, Roger S. Blumenthal, Mouaz H. Al-Mallah, Mahmoud Al Rifai

引用次数: 0

Using artificial intelligence to study atherosclerosis from computed tomography imaging: A state-of-the-art review of the current literature 利用人工智能研究计算机断层扫描成像中的动脉粥样硬化：最新文献综述

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.117580

Laura Valentina Klüner, Kenneth Chan, Charalambos Antoniades

{"title":"Using artificial intelligence to study atherosclerosis from computed tomography imaging: A state-of-the-art review of the current literature","authors":"Laura Valentina Klüner, Kenneth Chan, Charalambos Antoniades","doi":"10.1016/j.atherosclerosis.2024.117580","DOIUrl":"10.1016/j.atherosclerosis.2024.117580","url":null,"abstract":"<div><div>With the enormous progress in the field of cardiovascular imaging in recent years, computed tomography (CT) has become readily available to phenotype atherosclerotic coronary artery disease. New analytical methods using artificial intelligence (AI) enable the analysis of complex phenotypic information of atherosclerotic plaques. In particular, deep learning-based approaches using convolutional neural networks (CNNs) facilitate tasks such as lesion detection, segmentation, and classification. New radiotranscriptomic techniques even capture underlying bio-histochemical processes through higher-order structural analysis of voxels on CT images. In the near future, the international large-scale <u>O</u>xford <u>R</u>isk <u>F</u>actors <u>A</u>nd <u>N</u>on-invasive Imaging (ORFAN) study will provide a powerful platform for testing and validating prognostic AI-based models. The goal is the transition of these new approaches from research settings into a clinical workflow.</div><div>In this review, we present an overview of existing AI-based techniques with focus on imaging biomarkers to determine the degree of coronary inflammation, coronary plaques, and the associated risk. Further, current limitations using AI-based approaches as well as the priorities to address these challenges will be discussed. This will pave the way for an AI-enabled risk assessment tool to detect vulnerable atherosclerotic plaques and to guide treatment strategies for patients.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 117580"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141132423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling human atherosclerotic lesions in the test tube: Are we there yet? 在试管中模拟人类动脉粥样硬化病变：我们成功了吗？

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118560

Mary Gonzalez Melo, Arnold von Eckardstein, Jerome Robert

{"title":"Modeling human atherosclerotic lesions in the test tube: Are we there yet?","authors":"Mary Gonzalez Melo, Arnold von Eckardstein, Jerome Robert","doi":"10.1016/j.atherosclerosis.2024.118560","DOIUrl":"10.1016/j.atherosclerosis.2024.118560","url":null,"abstract":"<div><div>Atherosclerotic cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. Atherogenesis is a slow and life-long process characterized by the accumulation of lipoproteins and immune cells within the arterial wall. Atherosclerosis has been successfully modeled in animals: However, there are economic, ethical, and translational concerns when using these models. There is also growing recognition of the need for robust human-based <em>in vitro</em> systems that can faithfully recapitulate key aspects of human atherosclerosis. Such systems may offer advantages in terms of scalability, reproducibility, and ability to manipulate specific variables, thereby facilitating a deeper understanding of disease mechanisms and accelerating the development of targeted therapeutics. Leveraging innovative <em>in vitro</em> platforms holds promise in complementing traditional animal models of atherosclerosis. In the present review, we discuss the advantages and disadvantages of recently developed models of atherosclerosis and propose ideas to be considered when developing future generations of models.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118560"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Engineering next generation vascularized organoids 下一代血管化类器官构建体的工程设计

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118529

Nicolas Werschler , Clement Quintard , Stephanie Nguyen , Josef Penninger

引用次数: 0

Corrigendum to “Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis” [Atherosclerosis, Vol 396, (September 2024), 118528] 更正："迎接 21 世纪心肾代谢疾病的挑战：将证据转化为预防和控制动脉粥样硬化的最佳临床实践"[《动脉粥样硬化》，第 396 卷，（2024 年 9 月），第 118528 页]。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118610

International Cardiometabolic Working Group, Andrew Krentz , Stephan Jacob , Christian Heiss , Naveed Sattar , Soo Lim , Kamlesh Khunti , Robert H. Eckel

引用次数: 0

Progression of coronary artery calcium density and major adverse cardiovascular events 冠状动脉钙密度的进展与主要不良心血管事件。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118593

Qingchao Meng, Li Zhao, Na Zhao, Yunqiang An, Bin Lu , Yang Gao

{"title":"Progression of coronary artery calcium density and major adverse cardiovascular events","authors":"Qingchao Meng, Li Zhao, Na Zhao, Yunqiang An, Bin Lu , Yang Gao","doi":"10.1016/j.atherosclerosis.2024.118593","DOIUrl":"10.1016/j.atherosclerosis.2024.118593","url":null,"abstract":"<div><h3>Background and aims</h3><div>We aimed to investigate the relationship between coronary artery calcium (CAC) density progression and major adverse cardiovascular events (MACE), and the prognostic value of CAC density progression.</div></div><div><h3>Methods</h3><div>Patients with serial CAC scans were enrolled in this study. CAC density was directly measured in calcified lesions. Change and rate of progression of CAC density were calculated. Cox proportional hazard regression was utilized to estimate hazard ratios (HRs) for time to MACE regarding CAC density. The incremental prognostic value and the reclassification ability of CAC density progression were evaluated using the C-index and continuous net reclassification index (NRI).</div></div><div><h3>Results</h3><div>304 patients (57.86 ± 9.47 years, 69.4 % male) were included. There were 47 MACE over a follow–up period of 76.00 (56.00–95.00) months. After adjustment for risk factors and CAC volume, the change of CAC density was inversely associated with MACE (per 10HU: HR: 0.956, 95 % confidence interval: 0.920–0.992, <em>p</em> = 0.018). Adding the change of CAC density to risk factors and baseline CAC density improved the C-index (0.694 <em>vs.</em> 0.678, <em>p</em> = 0.026). Adding the change of CAC density improved reclassification of MACE compared with risk factors and baseline CAC density [NRI = 0.432 (0.016–0.789)].</div></div><div><h3>Conclusions</h3><div>CAC density progression is inversely associated with MACE. The addition of the change of CAC density improves prognostic value compared to baseline risk factors and CAC density and optimizes risk reclassification.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118593"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142379997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual role of lipids in chronic kidney disease: Pathogenic culprits and therapeutic allies 血脂在慢性肾病中的双重作用：致病元凶与治疗盟友。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118615

Elena Giardini , Dean Moore , Denise Sadlier , Catherine Godson , Eoin Brennan

引用次数: 0

Metabolites derived from radical oxidation of PUFA: NEO-PUFAs, promising molecules for health? 由 PUFA 自由基氧化产生的代谢物：NEO-PUFAs，有望促进健康的分子？

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118600

Anna Abramova , Jamie Bride , Camille Oger , Marie Demion , Jean-Marie Galano , Thierry Durand , Jérôme Roy

{"title":"Metabolites derived from radical oxidation of PUFA: NEO-PUFAs, promising molecules for health?","authors":"Anna Abramova , Jamie Bride , Camille Oger , Marie Demion , Jean-Marie Galano , Thierry Durand , Jérôme Roy","doi":"10.1016/j.atherosclerosis.2024.118600","DOIUrl":"10.1016/j.atherosclerosis.2024.118600","url":null,"abstract":"<div><div>Oxidative stress plays a critical role in numerous pathological processes. Under these stress conditions, the free radical-catalyzed lipid peroxidation generates <em>in vivo</em> a large number of key products that are involved in many physiological and pathophysiological processes. Among these products are neuroprostanes, which arise from the peroxidation of docosahexaenoic acid (DHA), and isoprostanes, resulting from arachidonic acid (AA) and eicosapentaenoic acid (EPA) through the same peroxidation process. These non-enzymatic oxygenated metabolites newly appointed NEO-PUFAs have gained recognition as reliable markers of oxidative stress in neurogenerative and cardiovascular diseases. Moreover, some of them display a wide range of biological activities. The ability to detect and measure these metabolites offers precious insights into the mechanisms of oxidative damage and holds potential therapeutic implications for various health conditions, including neurodegenerative diseases. This review focuses on the role of neuroprostanes as biomarkers for oxidative stress and related diseases, highlighting their potential applications in medical research and treatment.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118600"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nucleic acid liquid biopsies in cardiovascular disease: Cell-free DNA liquid biopsies in cardiovascular disease 心血管疾病中的核酸液体活检：心血管疾病中的无细胞 DNA 液体活检。

IF 4.9 2区医学

Atherosclerosis Pub Date : 2024-11-01 DOI: 10.1016/j.atherosclerosis.2024.118583

Tyler Artner, Smriti Sharma, Irene M. Lang

{"title":"Nucleic acid liquid biopsies in cardiovascular disease: Cell-free DNA liquid biopsies in cardiovascular disease","authors":"Tyler Artner, Smriti Sharma, Irene M. Lang","doi":"10.1016/j.atherosclerosis.2024.118583","DOIUrl":"10.1016/j.atherosclerosis.2024.118583","url":null,"abstract":"<div><div>Cardiovascular disease (CVD) is the leading cause of death worldwide, and despite treatment efforts, cardiovascular function cannot always be restored, and progression of disease be prevented. Critical insights are oftentimes based on tissue samples. Current knowledge of tissue pathology typically relies on invasive biopsies or postmortem samples. Liquid biopsies, which assess circulating mediators to deduce the histology and pathology of distant tissues, have been advancing rapidly in cancer research and offer a promising approach to be translated to the understanding and treatment of CVD. The widely understood elevations in cell-free DNA during acute and chronic cardiovascular conditions, associate with disease, severity, and offer prognostic value. The role of neutrophil extracellular traps (NETs) and circulating nucleases in thrombosis provide a solid rationale for liquid biopsies in CVD. cfDNA originates from various tissue types and cellular sources, including mitochondria and nuclei, and can be used to trace cell and tissue type lineage, as well as to gain insight into the activation status of cells. This article discusses the origin, structure, and potential utility of cfDNA, offering a deeper and less invasive approach for the understanding of the complexities of CVD.</div></div>","PeriodicalId":8623,"journal":{"name":"Atherosclerosis","volume":"398 ","pages":"Article 118583"},"PeriodicalIF":4.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0